Compare Johnson & Johnson (JNJ) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Sony Group Corp — how do they compare? Johnson & Johnson trades at $250.4 (market cap $598.96B), while Sony Group Corp trades at $21.12 (market cap $125.96B). The key difference: Johnson & Johnson is far larger — about 4.8× Sony Group Corp's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | SONY | |
|---|---|---|
Market Cap | $598.96B | $125.96B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $30.26 |
52-Week Low | $164.36 | $19.32 |
Enterprise Value | $631.90B | $122.45B |
Dividend Yield | 2.15% | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Sony trades at $21.165 with modest daily gains of 0.21%, supported by strong technical momentum and bullish analyst sentiment. The company demonstrates solid fundamentals with $12.96T in revenue and $1.14T net income for 2025, though recent Q1 2026 earnings missed expectations. Sony's entertainment strategy expansion and digital gaming transition position it for long-term growth despite near-term execution risks.
Sony presents a compelling investment case with strong cash flow generation and analyst support, though investors must monitor the digital gaming transition execution and potential revenue volatility. The stock's current valuation metrics appear reasonable given the company's market position and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
